PMID- 37022112
OWN - NLM
STAT- MEDLINE
DCOM- 20230802
LR  - 20230803
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 160
IP  - 2
DP  - 2023 Aug 1
TI  - Clinicopathologic features of non-type 1/2 gastric neuroendocrine tumors and 
      their associated mucosal changes.
PG  - 130-136
LID - 10.1093/ajcp/aqad021 [doi]
AB  - OBJECTIVES: The pathogenesis for non-type 1/2 gastric neuroendocrine tumors 
      (G-NETs) remains unclear. The aim of this study was to examine the 
      clinicopathologic features of G-NETs and associated mucosal changes. METHODS: The 
      electronic health records of patients with non-type 1/2 G-NETs were reviewed. H&E 
      slides were reviewed for pathologic features and mucosal changes. The t test and 
      Fisher exact test were used for statistical analysis. RESULTS: In total, 33 
      patients were assigned to either group 1 (n = 23) or group 2 (n = 10). Group 1 
      included patients with a history of proton pump inhibitor (PPI) use, increased 
      gastrin levels, or significant PPI effect (PPI/gastrin-associated). All other 
      patients were assigned to group 2. There was no significant difference in age and 
      sex between the 2 groups. Group 2 tumors were more likely to be larger, invade 
      deeper, and develop metastases (P < .05). Tumors in patients with cirrhosis 
      tended to be larger. Peritumoral mucosal changes included loss of oxyntic glands, 
      foveolar hyperplasia, and intestinal metaplasia. Background mucosa in group 1 
      patients showed PPI effect and neuroendocrine hyperplasia or dysplasia. 
      CONCLUSIONS: Although PPI/gastrin-associated non-type 1/2 G-NETs were smaller and 
      more indolent than typical type 3 G-NETs, tumors in patients with cirrhosis 
      tended to be larger. Additionally, peritumoral mucosal changes could mimic 
      chronic atrophic gastritis.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of American 
      Society for Clinical Pathology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Logan, Kristen
AU  - Logan K
AD  - Department of Pathology, Duke University Medical Center, Durham, NC, US.
FAU - Shi, Chanjuan
AU  - Shi C
AUID- ORCID: 0000-0001-5962-6479
AD  - Department of Pathology, Duke University Medical Center, Durham, NC, US.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Gastrins)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - *Neuroendocrine Tumors/pathology
MH  - Gastrins
MH  - Hyperplasia/pathology
MH  - *Stomach Neoplasms/pathology
MH  - Proton Pump Inhibitors
MH  - Gastric Mucosa/pathology
OTO - NOTNLM
OT  - cirrhosis
OT  - gastric neuroendocrine tumors
OT  - mucosal changes
OT  - non-type 1 and 2
OT  - proton pump inhibitor
EDAT- 2023/04/07 06:00
MHDA- 2023/08/02 06:42
CRDT- 2023/04/06 09:42
PHST- 2022/11/29 00:00 [received]
PHST- 2023/02/06 00:00 [accepted]
PHST- 2023/08/02 06:42 [medline]
PHST- 2023/04/07 06:00 [pubmed]
PHST- 2023/04/06 09:42 [entrez]
AID - 7109848 [pii]
AID - 10.1093/ajcp/aqad021 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2023 Aug 1;160(2):130-136. doi: 10.1093/ajcp/aqad021.